RE: Funding4 Sep 2025 22:38
Not sure they would have felt they had the option over whether to share these rather important results to their holders 1015?
They stated in their interims ...
" Whilst overall sales of CiRT tests have grown in the period under review, it remains clear that wider adoption of CiRT will be dependent on the test's inclusion in clinical guidelines and as a result the Company expects to apply for guideline inclusion, using data from the PROWES prospective clinical study, later this year."
So if they hadn't of shared holders would likely have been both convinced they'd kept the data to themselves as it was poor and all over them for updates til they did rns.